FDA Grants Priority Review to Bristol Myers Squibb’s Camzyos for Adolescent oHCM
Event summary
- FDA accepted Bristol Myers Squibb’s sNDA for Camzyos (mavacamten) to treat adolescents (12-18) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Priority Review designation sets PDUFA target action date of September 30, 2026.
- Approval would make Camzyos the first cardiac myosin inhibitor for adolescent oHCM patients.
- Phase 3 SCOUT-HCM trial met primary endpoint, showing significant reduction in Valsalva LVOT gradient.
- Camzyos is already approved for adult oHCM patients and has been prescribed to nearly 25,000 U.S. patients.
The big picture
This regulatory submission represents Bristol Myers Squibb’s push to extend its cardiovascular franchise into pediatric care, addressing a significant unmet need in adolescent oHCM patients. The Priority Review designation underscores the clinical urgency of this indication. Success here could further solidify Camzyos’ position as a cornerstone therapy in hypertrophic cardiomyopathy treatment across age groups.
What we're watching
- Approval Timing
- Whether the FDA will meet the September 30, 2026 PDUFA date for this expanded indication.
- Market Expansion
- How quickly Bristol Myers Squibb can penetrate the adolescent oHCM market if approved.
- Competitive Positioning
- Whether this move strengthens Bristol Myers Squibb’s leadership in the cardiac myosin inhibitor class.
Related topics